Sources checked against CMS.gov, FDA.gov, Medicare.gov, and Eli Lilly.

Does Medicare Cover Zepbound? Your Complete Coverage Guide

Published: March 25, 2026 · Last updated: July 3, 2026

Medicare does not cover Zepbound (tirzepatide) for weight loss under ordinary Part D rules. That exclusion has been federal law since 2003. But the coverage picture changed dramatically in late 2025 and early 2026, and there are now 3 distinct Medicare coverage routes — each with different eligibility, different costs, and different timelines.

Your 3 Pathways to Zepbound on Medicare

Sources: CMS.gov (March 2026 Bridge FAQs), Eli Lilly, FDA.

Most pages covering this topic only explain one of these lanes — usually the sleep apnea pathway — and leave you guessing about the rest. We're going to walk through all three, explain exactly who qualifies, what you'll actually pay, and give you a clear next step no matter where you land.

Why Doesn't Medicare Cover Zepbound for Weight Loss?

Before we get into the pathways, it helps to understand why this is so confusing in the first place.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes “agents when used for anorexia, weight loss, or weight gain” from Part D coverage. That law was written years before GLP-1 medications like Zepbound existed as a treatment category. It has never been updated.

In 2024, CMS proposed reinterpreting this exclusion to allow Part D coverage for anti-obesity medications — a move that drew enormous interest, since roughly 20% of Medicare enrollees (about 14 million people) have an obesity diagnosis. But in April 2025, the administration decided not to move forward with that reinterpretation.

So the law hasn't changed. But the workarounds have arrived.

• December 2024: The FDA approved Zepbound for a non-weight-loss indication — moderate-to-severe obstructive sleep apnea in adults with obesity. That opened the first Medicare coverage lane.
• December 2025: CMS announced the Medicare GLP-1 Bridge and the BALANCE Model — covering Zepbound for weight loss through separate demonstration authorities that bypass the Part D exclusion entirely.

That's why you're finding contradictory information online. Some articles were written before December 2025. Some only cover the sleep apnea angle. Some still say the 2026 expansion was rejected — which is technically true for the Part D reinterpretation, but misses the Bridge and BALANCE programs entirely. We verified every claim on this page against the CMS GLP-1 Bridge FAQ (updated March 2026), the BALANCE Model documentation, and the current FDA label.

Pathway 1: Can Medicare Cover Zepbound for Sleep Apnea Right Now?

What the FDA Approved

In December 2024, the FDA approved Zepbound for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. It's the first and only prescription medication approved specifically for this use. Because this is a non-weight-loss indication, it sidesteps Medicare's weight loss drug exclusion entirely.

Who This Applies To

You may qualify if you meet all of the following:

• You have a confirmed diagnosis of moderate-to-severe OSA (typically from a sleep study/polysomnography)
• You have obesity (generally BMI ≥ 30)
• You're enrolled in Medicare Part D (standalone PDP or Medicare Advantage with drug coverage)
• Your specific plan lists Zepbound on its formulary for the OSA indication
• Your prescription is written specifically for OSA — not for weight loss

How to Get Covered Through This Pathway

1. Confirm your OSA diagnosis. You'll need documentation of moderate-to-severe obstructive sleep apnea, usually from a sleep study. If you haven't had one, Medicare Part B covers diagnostic sleep tests when your doctor determines they're medically necessary.
2. Check your plan's formulary. Not all Part D plans have added Zepbound for the OSA indication. Use the Medicare Plan Finder at Medicare.gov to search your specific plan's formulary. Look for Zepbound (tirzepatide) and check which indications are covered.
3. Expect prior authorization. Nearly all plans require prior authorization for Zepbound. Your doctor will need to submit documentation including your sleep study results, BMI/obesity documentation, and a statement that Zepbound is being prescribed for OSA.
4. Understand your costs. Your actual cost through Part D depends on your specific plan's formulary tier, pharmacy, and which coverage phase you're in. The 2026 Part D benchmarks: deductible of up to $615, and a covered-drug out-of-pocket cap of $2,100 — once you hit that, you pay $0 for the rest of the year. If you qualify for Extra Help (Low-Income Subsidy), copays for covered brand-name drugs are generally up to $12.65, and some beneficiaries pay less or $0.

What to Say When You Call Your Plan

What If Your Plan Doesn't Cover It for OSA?

• Request a formulary exception. Medicare allows you and your prescriber to ask for an exception when a needed drug isn't on the formulary. Your doctor will need to provide a supporting statement explaining why Zepbound is medically necessary for your OSA.
• Switch plans during enrollment. You can change plans during the Annual Enrollment Period (October 15 – December 7) or, for Medicare Advantage, during the Medicare Advantage Open Enrollment (January 1 – March 31).
• Check the Bridge program below. If you want Zepbound for weight management and also happen to have OSA, read Pathway 2 carefully — but know that CMS has made clear: if your use is coverable under ordinary Part D (like OSA), you go through your Part D plan, not the Bridge.

Pathway 2: The Medicare GLP-1 Bridge Program ($50/Month — Open Now Through 2027)

This is the biggest development in Medicare GLP-1 coverage. Every detail below is verified against the CMS GLP-1 Bridge FAQ page (updated March 2026).

What the Bridge Program Is

This is not a Part D benefit. It's a separate CMS-administered program that uses its own central claims processor. Your Part D plan doesn't have to opt in. CMS manages the whole thing directly. At $50/month, the Bridge eliminates more than 95% of Zepbound's $1,086 list price.

Do You Qualify? The Specific Eligibility Criteria

To qualify for the Medicare GLP-1 Bridge, you must meet all of these baseline requirements:

• Enrolled in an eligible Part D plan type for 2026 — CMS includes standalone PDPs and MA coordinated care plans with drug coverage (HMO, HMO-POS, local/regional PPO), plus SNPs, EGWPs, and LI NET; some other plan types are excluded unless you're also in a standalone PDP
• At least 18 years old
• Prescribed Zepbound to reduce excess body weight and maintain weight reduction
• Combined with ongoing structured nutrition and physical activity

AND you must fall into one of these three BMI categories:

Your doctor submits a prior authorization request to CMS's central processor — not to your Part D plan — attesting that you meet these criteria.

5 Things Most People Don't Know About the Bridge

1. The $50 does NOT count toward your Part D out-of-pocket cap. The Bridge operates entirely outside your Part D benefit. That means your $50/month payments don't reduce your $615 deductible and don't count toward your $2,100 annual cap. This is additional spending, separate from everything else. It won't appear on your Part D Explanation of Benefits, and you can't spread the $50 across months using the Medicare Prescription Payment Plan.
2. Extra Help (Low-Income Subsidy) does NOT apply. Even if you qualify for Extra Help and pay little or nothing for other medications, you'll still owe the full $50/month under the Bridge. Over the full 18-month program, that's $900 — worth planning for.
3. You can't transfer an existing Part D prescription to the Bridge to save money. If your doctor already prescribes Zepbound through your Part D plan for OSA, that prescription stays with your Part D plan. The clinical indication on your prescription determines which pathway applies. CMS goes further: having a Part D-coverable diagnosis — type 2 diabetes, moderate-to-severe OSA, or noncirrhotic MASH (fatty liver disease) — makes you ineligible for the Bridge outright, even if your BMI otherwise qualifies.
4. Prior authorization goes to CMS, not your Part D plan. This is a different process than what you're used to. Your doctor sends the prescription to the pharmacy and, when requested, completes the prior authorization through the CMS central processor — not your insurance company. If approved, you'll get a letter in the mail, and the authorization stays valid through December 31, 2027 (including refills and dose changes) unless you switch GLP-1s.
5. The Bridge runs 18 months. It runs July 1, 2026 through December 31, 2027. BALANCE will not launch for Medicare Part D in 2027 — CMS extended the Bridge instead. After December 2027, coverage will depend on whether BALANCE launches for Medicare Part D in 2028.

How to Start Now (the Bridge Is Open)

The Bridge is open. Here's the process, straight from Medicare.gov:

1. Confirm you're enrolled in an eligible plan type. Standalone PDPs and MA coordinated care plans with drug coverage qualify, along with SNPs, EGWPs, and LI NET. If you're in Original Medicare with no drug coverage, you're not eligible.
2. Confirm you're Bridge-eligible, not Part D-routed. If you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease — or you already get a GLP-1 through your Part D plan — you're not eligible for the Bridge. Your Part D plan is the lane to check instead.
3. Document your qualifying criteria with your doctor. BMI and health conditions are assessed as of when GLP-1 therapy starts — if you began therapy before July 1, eligibility can be based on your status at initiation. Gather lab results, blood pressure readings, A1c levels, and records of cardiac events.
4. Make sure the prescription is for Zepbound KwikPen. The Bridge doesn't cover single-dose Zepbound vials or pens.
5. Have your doctor send the prescription and complete the prior authorization. The pharmacy may ask for your Medicare Number or the last 4 digits of your Social Security number. Your provider certifies the medication is part of a lifestyle program focused on diet and exercise. Watch the mail for your approval letter — it stays valid through December 31, 2027 (including refills and dose changes) unless you change GLP-1s.

Pathway 3: The BALANCE Model — What Happens After the Bridge Ends

The Bridge is an 18-month program (July 2026–December 2027). The longer-term plan is the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), designed to provide ongoing Medicare Part D coverage of GLP-1 medications for weight management.

What BALANCE Is

BALANCE is a CMS Innovation Center payment model that allows Medicare Part D plans to cover GLP-1s (including Zepbound and Wegovy) for weight management — something they're normally prohibited from doing. Beneficiaries receiving GLP-1s for weight management under BALANCE will also have access to a manufacturer-provided lifestyle support program at no cost.

Start dates:

• Medicare Part D: BALANCE will not launch in 2027 — CMS confirmed on April 30, 2026 that the participation threshold was not met, postponed the Part D portion indefinitely, and extended the Bridge through December 2027 instead. CMS will use Bridge utilization data to decide whether BALANCE proceeds; 2028 is the earliest realistic start, and it is not guaranteed.
• Medicaid: launched May 2026 (state by state, scheduled to run through 2031)

Why 2027 Is Not Guaranteed

The Kaiser Family Foundation has flagged this transition risk as one of the program's biggest concerns. It's a structural risk of how these programs are designed, not a scare tactic.

What You Should Do About This

• Nothing this fall — that's the good news. Because the Bridge was extended through 2027 and runs outside Part D, you don't need to switch plans for 2027 to keep $50/month access.
• Watch fall 2027 instead. If CMS revives BALANCE for 2028, plan participation will matter during the October 15 – December 7, 2027 enrollment window.
• If BALANCE does return, weigh a plan switch against the impact on your other medications.

Cost-sharing under BALANCE varies by plan type and benefit phase: during the deductible phase, up to $245 plus a dispensing fee per fill; initial coverage phase, Enhanced Alternative and EGWP plans cap cost-sharing at $50, while other plans cap at $125; catastrophic phase, $0.

Eligibility for BALANCE

The eligibility criteria are broader than the Bridge. Under BALANCE, you may qualify if you have:

• Type 2 diabetes
• Noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis (stages F2–F3)
• Obstructive sleep apnea
• Obesity with lifestyle modification and meeting BMI criteria similar to the Bridge

How to Actually Get Medicare to Cover Zepbound (Step by Step)

Understanding the pathways is one thing. Actually navigating the system is another. Here's a practical walkthrough that applies no matter which pathway you're pursuing.

Step 1: Get the Indication Right

This is where most people stumble before they even start. For ordinary Part D coverage, the only current indication that works is moderate-to-severe obstructive sleep apnea in adults with obesity. If your doctor writes a prescription that says “for weight loss” or “for obesity,” your Part D plan will deny it — and that's not the plan being difficult, it's federal law.

For the Bridge program (starting July 2026), the indication is explicitly weight management — so the prescription should reference weight reduction. But if your doctor is already prescribing Zepbound for OSA through your Part D plan, you can't switch that same prescription to the Bridge for a lower copay.

Step 2: Confirm Your Coverage Route

There are now two completely separate prior authorization tracks:

• For OSA coverage: Prior authorization goes to your Part D plan
• For Bridge program weight loss coverage: Prior authorization goes to CMS's central processor (a completely different system)

Step 3: Check Formulary and Utilization Rules

For the OSA pathway, your plan may have specific utilization management requirements:

• Prior authorization: Nearly universal for Zepbound. Your doctor submits documentation before the pharmacy can fill the prescription.
• Step therapy: Plans may require you to try a lower-cost formulary drug first before approving Zepbound.
• Quantity limits: Plans may limit the quantity dispensed per fill.
• Tier placement: Brand-name specialty drugs like Zepbound are often placed on higher tiers, meaning coinsurance rather than a flat copay.

Step 4: Help Your Doctor Build the Strongest Prior Authorization

Prior authorization requests get approved far more often when the documentation is thorough. Make sure your doctor includes:

• Your complete diagnosis with supporting evidence (sleep study results for OSA, recent lab work for Bridge-qualifying conditions)
• Your BMI with a recent date of measurement
• A clear statement of medical necessity explaining why you need Zepbound specifically
• What alternatives have been tried and why they were insufficient, ineffective, or contraindicated
• The exact FDA-approved indication being targeted
• Relevant clinical guidelines supporting the use of Zepbound for your condition

Step 5: Know What to Do When the First Answer Is No

A denial is a decision, not a dead end. Medicare gives you formal appeal rights, and many initial denials get overturned when proper documentation is submitted on the second try. Common fixable issues include incomplete paperwork and using the wrong indication on the prescription — both can be corrected and resubmitted. See the full denial section below.

Why Do Different Websites Say Different Things?

If you've been researching this topic for more than ten minutes, you've probably noticed that answers contradict each other. There are three reasons:

• Timing. Many articles were published before December 23, 2025 — the date CMS announced the Bridge and BALANCE programs. At least one major pharmacy information site still says CMS “decided against” expanding coverage in 2026, which was true for the Part D reinterpretation but completely misses the Bridge program.
• Confusing sleep apnea coverage with weight loss coverage. Some pages explain that Medicare covers Zepbound for OSA and then leave the impression that weight loss coverage is available too. It's not — not through ordinary Part D. The Bridge is a separate program with separate rules.
• Confusing the Bridge with Part D. The Bridge operates outside Part D. The $50 copay, the eligibility criteria, the prior authorization process, and the financial accounting are all separate. Pages that lump everything together create the wrong expectations.

How Much Does Zepbound Actually Cost on Medicare?

Here's every scenario in one place:

Prices verified July 3, 2026. Sources: CMS.gov, LillyDirect, Eli Lilly press releases, Medicare.gov.

Can Medicare Beneficiaries Use the Zepbound Savings Card?

There are two different Lilly programs, and the distinction matters:

• The commercial insurance savings card (which reduces cost to as low as $25/month for commercially insured patients) excludes government insurance beneficiaries — including Medicare, Medicaid, TRICARE, and VA. If you have Medicare, this card won't work at the pharmacy.
• The self-pay program through LillyDirect is a separate pathway — a cash-pay option available to anyone with a prescription, including Medicare beneficiaries who are paying out of pocket. This is how you access the $299–$449/month pricing described above.

What If Medicare Denies Coverage for Zepbound?

Denials happen — and they're not the end of the road. A denial is a decision that can be appealed, and many initial denials result from incomplete documentation rather than a fundamental eligibility problem. The difference between approval and denial often comes down to how thoroughly the paperwork was prepared.

Understanding Why You Were Denied

Before you do anything else, find out the specific reason for the denial. Common denial reasons include:

• Wrong indication on the prescription. If it says “weight loss” instead of “obstructive sleep apnea,” Part D coverage won't happen under current rules. This is the single most common fixable error.
• Incomplete documentation. Missing sleep study results, no recent BMI on file, or a vague medical necessity letter.
• Plan formulary exclusion. Zepbound isn't on your specific plan's formulary for the indication being requested. This doesn't mean it can't be covered — it means you need a formulary exception.
• Step therapy requirement not met. Your plan may require you to try a lower-cost covered drug first. If you've already tried required medications, make sure that's documented.
• Prior authorization not submitted properly. Wrong form, missing signature, sent to the wrong fax number.

Your Formal Appeal Rights

What Makes a Strong Appeal Package

• A detailed letter from your prescribing physician explaining exactly why Zepbound is medically necessary for your specific situation
• Complete diagnosis documentation — sleep study results, lab work, imaging
• Your BMI with a recent date of measurement
• A clear explanation of what alternatives have been tried and why they didn't work
• The specific FDA-approved indication for which Zepbound is being prescribed
• Any relevant clinical guidelines or medical literature supporting the use
• A direct response to the reason given for the denial

You Can Also Request a Formulary Exception

This is different from an appeal. A formulary exception asks the plan to cover a drug that isn't normally on their formulary. Your doctor must provide a written medical justification explaining why the formulary alternatives won't work for you specifically. Plans are required by Medicare to have an exception process. The worst they can say is no — and even then, you have the appeal rights described above.

Key Dates: Your Medicare Zepbound Timeline

There's a lot happening in a short window. Here are the dates that matter:

The enrollment window in October–December 2027 will be particularly important — that's when you'll need to make sure your 2028 plan participates in BALANCE (if CMS runs a new participation round).

Does Medicare Cover Zepbound for These Specific Conditions?

These are the most common condition-specific searches we see. Here's a direct answer for each one.

Medicare Part D vs. Medicare Advantage: Which Covers Zepbound?

• Original Medicare + Standalone Part D (PDP): This is the standard route. Part D covers outpatient prescription drugs including Zepbound (when the indication qualifies). Check your plan's formulary at Medicare.gov.
• Medicare Advantage with Drug Coverage (MA-PD): MA plans that include Part D drug coverage follow the same federal exclusion for weight loss drugs. They can cover Zepbound for OSA if it's on their formulary. MA-PD enrollees are also eligible for the GLP-1 Bridge program.
• Medicare Advantage Without Drug Coverage: If your MA plan doesn't include prescription drug benefits, it won't cover Zepbound at all.
• Part B: Generally no. Part B typically covers drugs that aren't self-administered — think infusions at a doctor's office. Zepbound is a self-administered injection (you give it to yourself at home), so the practical Medicare route is Part D, not Part B.
• The Bridge is administered by CMS, not your Part D plan. You need to be enrolled in an eligible Part D plan type — CMS includes standalone PDPs and MA coordinated care plans with drug coverage, plus SNPs, EGWPs, and LI NET — and meet the clinical criteria.

What If You Don't Qualify for the Bridge? Options Available Right Now

Pathway 1 requires a sleep apnea diagnosis. Pathway 2 is open now — but not everyone qualifies, approval isn't instant, and it only covers the KwikPen. Pathway 3 is postponed indefinitely. And here's the group almost nobody writes for: if your BMI is between 27 and 34.9 without one of the qualifying conditions — or under 27 — there is currently no Medicare pathway for you at all. If that's you, or you're waiting on a prior authorization decision, or your plan type is excluded, here's what's actually available today.

Self-Pay Through LillyDirect

Eli Lilly sells Zepbound directly to patients through its LillyDirect platform. No insurance required. Pricing as of March 2026:

• 2.5 mg (starter dose): $299/month
• 5 mg: $399/month
• 7.5 mg through 15 mg (maintenance doses): $449/month

These are for single-dose vials and the newer multi-dose KwikPen (launched February 2026). Both require a prescription from a licensed provider. To maintain the $449 maintenance dose pricing, you need to refill within 45 days of your previous delivery.

The Self-Pay Bridge Math

Here's what this looked like in real dollars for someone who started self-pay in April and moved to the Bridge when it opened in July:

Compare that to $1,086/month at full retail ($9,774 over the same period). The math often makes more sense than people expect — especially when weighed against the downstream health costs of untreated obesity: higher blood pressure medications, sleep apnea equipment, joint replacements, diabetes management.

Starting today, the math is simpler: self-pay only has to cover the gap between your first fill and your Bridge approval — then you're at $50/month through December 2027. And an underrated detail: Medicare assesses the clinical criteria as of when you start GLP-1 therapy, including therapy started before July 1. Beginning on self-pay now doesn't disqualify you from the Bridge later.

Telehealth Providers Who Prescribe Zepbound

If your primary care doctor doesn't prescribe GLP-1 medications, or if you want a streamlined process, telehealth platforms can help. Ro is one option that prescribes FDA-approved Zepbound with medical oversight, licensed providers, and pharmacy fulfillment.

What makes Ro particularly relevant for Medicare beneficiaries: they prescribe the actual FDA-approved product — not a compounded version — which means if you start through Ro and later qualify for the Bridge or a BALANCE-participating plan, you're already established on the same medication. That can make the transition smoother when coverage kicks in.

A Note on Compounded Tirzepatide

Some online providers offer compounded tirzepatide at lower prices. We want to be direct about this:

• Compounded medications are not FDA-approved
• They are not the same product as brand-name Zepbound
• They will not be covered under any Medicare pathway — not Part D, not the Bridge, not BALANCE
• The FDA has issued warnings about certain compounded GLP-1 marketing practices

For Medicare beneficiaries specifically, brand-name Zepbound positions you to take advantage of the Bridge and BALANCE programs when they become available. Compounded tirzepatide does not.

What Other Medicare-Covered Options Exist?

If Zepbound isn't an option right now, Medicare does cover several weight-management related services available today:

• Sleep studies: Medicare Part B covers diagnostic sleep tests when your doctor determines they're clinically indicated. If you suspect you have sleep apnea, this is the first step toward the OSA coverage pathway for Zepbound.
• CPAP therapy: Medicare may cover a 12-week CPAP trial if you're diagnosed with obstructive sleep apnea and meet the coverage conditions.
• Obesity behavioral counseling: Medicare Part B covers intensive behavioral therapy for obesity (BMI ≥ 30) when provided in a primary care setting. This is counseling — not medication — but it's covered and can complement your weight management plan.
• Bariatric surgery: For qualifying patients, Medicare covers certain bariatric procedures including gastric bypass and sleeve gastrectomy.

None of these replace the effectiveness of GLP-1 medications for many patients. But they're covered, available now, and can be part of a comprehensive approach — especially while you work through a prior authorization, or if you don't qualify for the Bridge. See also our complete guide on Medicare coverage for Wegovy.

Your Action Plan: What to Do Based on Your Situation

How We Verified This Page

Trust matters on a topic like this, so here's exactly how we built and maintain this page:

• CMS GLP-1 Bridge FAQ page (cms.gov) — Bridge dates, eligibility criteria, $50 copay, plan-type eligibility, TrOOP exclusion, central processor details, and the rule that Bridge cannot be used for indications coverable under basic Part D
• Medicare.gov GLP-1 Bridge enrollee page (medicare.gov/glp1bridge) — beneficiary eligibility checklist, plan type eligibility, step-by-step prior authorization process, and the six qualifying conditions verified July 3, 2026
• CMS BALANCE Model (cms.gov) — 2027 timeline, cost-sharing by plan type and benefit phase, participation threshold, KwikPen formulation detail, lifestyle support program requirements, and eligibility criteria
• Medicare.gov Part D costs — 2026 Part D deductible cap ($615) and covered-drug out-of-pocket cap ($2,100)
• Medicare.gov Extra Help — 2026 LIS cost-sharing amounts by category
• Zepbound savings and pricing (zepbound.lilly.com) — commercial savings card exclusions, self-pay program terms, and LillyDirect pricing
• Medicare appeals (medicare.gov) — appeal levels, timelines, expedited review criteria
• FDA Zepbound label (accessdata.fda.gov) — approved indications (chronic weight management and moderate-to-severe OSA in adults with obesity)

We review this page against CMS sources at least monthly, and immediately when CMS, FDA, or Eli Lilly announce policy or pricing changes. The “Last Verified” date at the top reflects our most recent full review.

What we do NOT claim: We don't maintain a database of every Part D plan's Zepbound formulary status by ZIP code. Plans change their formularies, and the only authoritative source for your specific plan's coverage is the plan itself or the Medicare Plan Finder tool.

Frequently Asked Questions

The Bottom Line

Medicare's relationship with Zepbound is complicated — but it's no longer a dead end.

If you have sleep apnea, coverage may be available right now through your Part D plan. If you want it for weight management, the $50/month Bridge program is open right now and runs through December 31, 2027. What happens in 2028 depends on whether CMS moves forward with the BALANCE Model — it's postponed indefinitely, and CMS will use Bridge data to decide.

None of these pathways are automatic. They all require documentation, the right indication, and often a prior authorization. But the paths exist — and knowing which one applies to your situation is more than half the battle.

Still not sure which GLP-1 program is right for you?

Or if you're ready to start on self-pay today: